The global biotechnology race is intensifying, with the U.S. and China competing for dominance, impacting national security, economic balance, and technological progress. The National Security Commission on Emerging Biotechnology warns…
Edesa Biotech welcomes Peter J. Weiler as the new financial leader, effective May 1, 2025, to invigorate the company's strategic ambitions. Weiler's robust background includes roles at Exzell Pharma, Cipher…
Edesa Biotech appoints Peter J. Weiler as Chief Financial Officer effective May 1, 2025, succeeding Stephen Lemieux. Weiler brings extensive experience from his leadership role at Exzell Pharma and holds…
Edesa Biotech appoints Peter J. Weiler as the new Chief Financial Officer, effective May 1, 2025, succeeding Stephen Lemieux. Weiler's extensive background spans key roles at Exzell Pharma, Biosyent Inc.,…
Wacker Biotech and RNAV8 Bio have formed a strategic partnership to advance mRNA therapeutics. Wacker Biotech brings its expertise in microbial fermentation, processing up to 650 liters of material, to…
Wacker Biotech and RNAV8 Bio are collaborating to revolutionize mRNA-based therapies. Wacker Biotech brings expertise in pDNA/mRNA manufacturing and lipid nanoparticle (LNP) formulation. RNAV8 Bio specializes in optimizing noncoding mRNA…
The biotech and pharmaceutical industries face significant layoffs as companies like Nkarta and Alector realign strategies, aiming for operational efficiency and innovation. Major players, including Novartis, are restructuring to align…
A significant restructuring is occurring within the U.S. FDA and HHS, affecting thousands of positions and raising concerns about the future of innovative medicine in America. Peter Marks, former director…
Investing in Biotech: The XBI Opportunity The SPDR S&P Biotech ETF, known by its ticker XBI, stands out as a prime investment vehicle within the U.S. biotechnology landscape. Managed by…
Evaxion Trajectory Shift Evaxion Biotech (NASDAQ: EVAX) has just implemented a significant change to its American Depositary Shares (ADS) ratio, set in motion from January 14, 2025. Previously, each ADS…